NVN Liquidation Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Scott Plesha

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	1.6yrs
Yönetim Kurulu ortalama görev süresi	Veri yok

Son yönetim güncellemeleri

Recent updates

CEO

Scott Plesha (58 yo)

less than a year

Görev süresi

Mr. Scott M. Plesha is Chief Executive Officer of Ligand Pharmaceuticals Incorporated from April 2024. Mr. Plesha had been the President of BioDelivery Sciences International, Inc. since December 2017 and...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
John Gay	Chief Financial Officer	5.3yrs	US$568.23k	0.17% $ 0.05
Scott Plesha	CEO & Director	less than a year	Veri yok	Veri yok
Carri Geer	Senior VP & CTO	5.3yrs	Veri yok	Veri yok
Sai Rangarao	Senior VP	less than a year	Veri yok	Veri yok
Tomoko Maeda-Chubachi	Chief Medical Officer	2.8yrs	Veri yok	Veri yok
Melvin Whitehead	Senior Vice President of Manufacturing Operations	less than a year	Veri yok	Veri yok

1.6yrs

Ortalama Görev Süresi

Deneyimli Yönetim: 0A4P 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.6 yıl), bu da yeni bir ekibin varlığını gösteriyor.

NVN Liquidation Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

Recent updates

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Nasdaq To Delist the Common Stock of Novan

Novan, Inc.(OTCPK:NOVN.Q) dropped from NASDAQ Composite Index

Novan's Securities to Be Delisted from Nasdaq

Novan Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding MVLS Requirement

First quarter 2023 earnings released: US$0.54 loss per share (vs US$0.71 loss in 1Q 2022)

Novan, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings released: US$1.42 loss per share (vs US$1.74 loss in FY 2021)

Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (Sb206) for the Treatment of Molluscum Contagiosum

Forecast to breakeven in 2025

Novan, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Second quarter 2022 earnings released: US$0.44 loss per share (vs US$0.39 loss in 2Q 2021)

Novan Announces Publication of Positive Results from Pivotal Phase 3 Study of Berdazimer Gel, 10.3% (Sb206) in Patients with Molluscum Contagiosum in Jama Dermatology

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $14.968192 million.

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

First quarter 2022 earnings released: US$0.71 loss per share (vs US$0.60 loss in 1Q 2021)

Novan, Inc. to Report Q1, 2022 Results on May 16, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Novan, Inc. to Report Fiscal Year 2021 Results on Feb 22, 2022

Insufficient new directors

Third quarter 2021 earnings released: US$0.34 loss per share (vs US$0.63 loss in 3Q 2020)

Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi